Skip to main content

All Publications

Miguel Villalona Calero, Miami Cancer InstituteFollow

Phase II randomized, double-blind, placebo-controlled study of tivantinib in men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Publication Date

2018

Content Type

Article

PubMed ID:

Additional Authors:

Additional authors and institutional affiliations

Citation

Investigational New Drugs (2018) 36(5):919-926

Restricted

Available to BHSF community via local IP address or BHSF login.

Find in your library

COinS